Babelghaith Salmeen D, Wajid Syed, Alrabiah Ziyad, Othiq Mohammed Abdu M, Alghadeer Sultan, Alhossan Abdulaziz, Al-Arifi Mohamed, Attafi Ibraheem M
Department of Clinical Pharmacy, College of Pharmacy King Saud University, Riyadh, Saudi Arabia.
Ministry of Health, Sabya General Hospital, General Directorate of Health Affairs, Jazan, Saudi Arabia.
Risk Manag Healthc Policy. 2020 May 6;13:373-378. doi: 10.2147/RMHP.S247686. eCollection 2020.
This study examined the incidence of drug-related problems (DRPs) in different inpatient departments along with the medical team response to pharmacist's action in addressing DRPs at Jazan Hospital, Saudi Arabia.
This retrospective study was conducted among inpatients at Ministry of Health hospital in Jazan, a region in southwestern Saudi Arabia. We collected data for a 2-year period (from 2016 to 2017). For any detected DRP of the ordered medications for dispensing, the inpatient pharmacist is sending report for that particular DRP with recommendation to the medical team which in turn might accept or reject such recommendation. Serious drug-drug interactions, as part of DRP, were assessed by utilizing three different online DDI checkers, including Lexi-Comp, Medscape, and Drugs.com.
The most common type of DRP was serious drug-drug interactions (49%). Over the study period, most incidences of DRPs were decreased. Of the DRPs in 2016 and 2017, antibiotics were the most commonly involved (51% and 69.5%) of cases, respectively, followed by proton pump inhibitors (25.3% and 14.1%) and statins (12.9% and 9.4%). Interestingly, of the 241 interventions for DRPs in 2016, 199 (82.5%) were accepted, resulting in a change in drug therapy (p=0.006). In 2017, 90 (70.3%) interventions out of 128 were accepted by the physician and the drug therapy changed (p=0.029).
Pharmacist interventions appear to decrease the incidence of DRPs, which emphasize the importance of an optimal pharmaceutical care plan for clinical care settings.
本研究调查了沙特阿拉伯吉赞医院不同住院科室药物相关问题(DRP)的发生率,以及医疗团队对药剂师解决DRP措施的反应。
本回顾性研究在沙特阿拉伯西南部地区吉赞的一家卫生部医院的住院患者中进行。我们收集了2年期间(2016年至2017年)的数据。对于任何检测到的医嘱配药中的DRP,住院药剂师会就该特定DRP发送报告并向医疗团队提出建议,医疗团队可能会接受或拒绝该建议。作为DRP的一部分,严重药物相互作用通过使用三种不同的在线药物相互作用检查工具进行评估,包括Lexi-Comp、Medscape和Drugs.com。
最常见的DRP类型是严重药物相互作用(49%)。在研究期间,大多数DRP的发生率有所下降。在2016年和2017年的DRP中,抗生素分别是最常涉及的病例(51%和69.5%),其次是质子泵抑制剂(25.3%和14.1%)和他汀类药物(12.9%和9.4%)。有趣的是,在2016年针对DRP的241次干预中,199次(82.5%)被接受,导致药物治疗发生改变(p=0.006)。在2017年,128次干预中有90次(70.3%)被医生接受,药物治疗发生改变(p=0.029)。
药剂师的干预似乎降低了DRP的发生率,这强调了在临床护理环境中制定最佳药学服务计划的重要性。